Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jabil Inc (JBL) vs Merck & Co., Inc. (MRK) Price & Performance

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Jabil Inc vs Merck & Co., Inc. — how do they compare? Jabil Inc trades at $360.5 (market cap $37.37B), while Merck & Co., Inc. trades at $130.36 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 8.6× Jabil Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

JBLMRK
Market Cap
$37.37B$321.77B
Sector
TechnologyHealth
52-Week High
$385.50$131.84
52-Week Low
$192.49$77.60
Enterprise Value
$39.90B$368.53B
Dividend Yield
0.09%2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

Read more on JBL

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK